Fighting drug-resistant bacteria with a new genre of antibodies

4625634104_3c5ce7d178_m
Anti-Cancer Antibodies (Photo credit: PNNL – Pacific Northwest National Laboratory)

Laboratory experiments showed that the colloid antibodies attached to and inactivated only their intended targets without harming other cells

In an advance toward coping with bacteria that shrug off existing antibiotics and sterilization methods, scientists are reporting development of a new family of selective antimicrobial agents that do not rely on traditional antibiotics. Their report on these synthetic colloid particles, which can be custom-designed to recognize the shape of specific kinds of bacteria and inactivate them, appears in the Journal of the American Chemical Society.

Vesselin Paunov and colleagues point out that many bacteria have developed resistance to existing antibiotics. They sought a new approach — one that bacteria would be unable to elude by mutating into drug-resistant forms. Their inspiration was the antibodies that the immune system produces when microbes invade the body. Those antibodies patrol the body for microbes and bind to their surfaces, triggering a chain of events in which the body’s immune system attacks and destroys the microbes.

Paunov’s team describes development and successful tests of synthetic colloid particles, called “colloid antibodies.” Colloids are materials in which tiny particles of one material are dispersed in another material. Milk is a colloid in which globules of fat are spread throughout water and other materials. The colloid antibody particles are shells packed with a killing agent. They are designed to recognize and bind to specific bacteria.

Laboratory experiments showed that the colloid antibodies attached to and inactivated only their intended targets without harming other cells. “We anticipate that similar shape selective colloid antibodies can potentially become a powerful weapon in the fight against antibiotic-resistant bacteria,” say the researchers. “They can also find applications as non-toxic antibacterial agents, preventing growth of harmful bacteria in various formulations.”

See Also

 

The Latest Bing News on:
Drug resistant bacteria
The Latest Google Headlines on:
Drug resistant bacteria
[google_news title=”” keyword=”drug resistant bacteria” num_posts=”10″ blurb_length=”0″ show_thumb=”left”] [/vc_column_text]
The Latest Bing News on:
Colloid antibodies
  • Parkinson's disease progression slowed by antibody infusions
    on April 15, 2024 at 1:11 pm

    A drug that targets a build-up of proteins linked to Parkinson’s disease could slow the progression of motor symptoms in people with advanced forms of the condition. Although this shows promise ...

  • Monoclonal Antibodies in Rheumatoid Arthritis
    on April 11, 2024 at 5:00 pm

    No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

  • Production of monoclonal antibodies - Higher
    on February 13, 2024 at 9:10 am

    Antibodies bind to specific antigens on pathogens. This means that only one type of antibody will bind to a matching antigen. For example, an antibody that can recognise an antigen on the ...

  • What You Need To Know About Your Spleen
    on January 19, 2024 at 1:49 pm

    The white pulp also helps produce antibodies. While the spleen is the largest organ ... magnetic resonance imaging (MRI), positron emission tomography (PET) scans, liver-spleen colloid scanning, and ...

  • Are We Leaving Useful Antibodies Behind? The Value Of Non-Neutralizing Protective Monoclonal Antibodies
    on April 25, 2023 at 5:09 am

    Opinions expressed by Forbes Contributors are their own. While common sense may suggest that antibodies that do not neutralize the SARS-CoV-2 virus are of little value, recent studies show they ...

  • Colloids and surfaces. B, Biointerfaces
    on December 31, 2022 at 4:00 pm

    Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants.

  • Artificial Intelligence for better antibody drugs: ready for prime time?
    on November 6, 2022 at 4:00 pm

    The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

  • Antibody production services: anti-idiotype antibodies
    on May 19, 2022 at 3:08 am

    Anti-idiotypic antibodies (anti-ID Ab) are antibodies that identify and attach to the idiotypic center of other antibodies. Anti-idiotype antibodies are commonly employed in therapeutic drug ...

  • CD3 proteins: Targets for bispecific antibodies
    on February 13, 2022 at 1:24 pm

    A bispecific antibody (BsAb) is a type of artificial protein with the ability to bind to two distinct antigens or two epitopes of one antigen at the same time. Bispecific antibodies can assume a ...

  • Colloid & Interface Science Group
    on February 4, 2022 at 2:24 am

    The Colloid and Interface Science Group is one of the RSC's many Interest Groups. The Interest Groups are member driven groups which exist to benefit RSC members, and the wider chemical science ...

The Latest Google Headlines on:
Colloid antibodies

[google_news title=”” keyword=”colloid antibodies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top